Fabio Arcidiacono, Radiation Oncologist at S.Maria Hospital, shared a post on X:
“Localised setting.
POPART trial: predictors toxicity and oncological outcomes salvage SAbR prostate bed
oligo-R hormone-sensitive
2.PERSIAN trial: ADT-APA vs ADT-APA + SAbR
3. substudy RADIOSA trial: liquid biopsy molecular characterization.”
More posts featuring ESTRO25.
